Toshiaki Hanafusa

Toshiaki Hanafusa

Auto-generated profile, based on publicly available information

Toshiaki Hanafusa

Sakai City Medical Center, Sakai, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FHFumitaka Haseda
Fumitaka Haseda
AIAkihisa Imagawa
Akihisa Imagawa
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa
SMShinobu Mitsui
Shinobu Mitsui
CTChiharu Tsutsumi
Chiharu Tsutsumi
THToshiaki Hanafusa
Toshiaki Hanafusa
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D. First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC). Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC. The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.

18 March 2014 in Rheumatology International
Verified
Journal Article
Open access
PDF file
HSHideyuki Shiba
Hideyuki Shiba
TTTohru Takeuchi
Tohru Takeuchi
KIKentaro Isoda
Kentaro Isoda
YKYasuhito Kokunai
Yasuhito Kokunai
YWYumiko Wada
Yumiko Wada
THToshiaki Hanafusa
Toshiaki Hanafusa
Autoimmune disorder is one of the important side effects of interferon-α therapy. Some polymyositis cases as complication of interferon-α therapy were reported, but dermatomyositis were rarely. We report a case of dermatomyositis as a complication of interferon-α therapy for hepatitis C. A 52-year-old Japanese man was treated by combination therapy with pegylated interferon-α-2b and ribavirin for hepatitis C. Three months after the initiation of therapy, he showed erythema in the posterior cervical to dorsal and anterior cervical to thoracic regions, weight loss, general malaise, muscle pain, and severe increase in levels of muscle enzymes. We made a diagnosis of dermatomyositis according to these clinical features, proximal muscle-predominant myogenic change on electromyography, and infiltration of monocytes and CD4+-dominant lymphocytes on skin biopsy, although myositis-associated antibodies were absent. He was successfully treated with intravenous immunoglobulin and tacrolimus in addition to glucocorticoid. This is a very rare case of dermatomyositis associated with interferon-α therapy. We reviewed several similar published cases and the association of dermatomyositis and type I interferon.

1 July 2011 in Leukemia Research
Verified
Journal Article
Closed access
SNShoko Nakayama-Ichiyama
Shoko Nakayama-Ichiyama
TYTaiji Yokote
Taiji Yokote
NHNobuya Hiraoka
Nobuya Hiraoka
KIKazuki Iwaki
Kazuki Iwaki
ATAyami Takayama
Ayami Takayama
THToshiaki Hanafusa
Toshiaki Hanafusa

1 January 2014 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KIKentaro Isoda
Kentaro Isoda
TTTohru Takeuchi
Tohru Takeuchi
TKTakuya Kotani
Takuya Kotani
SHSuzue Hirano-Kuwata
Suzue Hirano-Kuwata
TSTakeshi Shoda
Takeshi Shoda
THToshiaki Hanafusa
Toshiaki Hanafusa
Objective Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs). The coadministration of PPIs increases the blood concentration of TAC due to drug interaction. We retrospectively investigated the influence of the coadministration of PPIs and CNIs, as well as the influence of the cytochrome P450 (CYP) 2C19 gene polymorphism status, on the blood concentrations of TAC and CSA in patients with CTDs. Methods Patients treated with TAC (n=35) or CSA (n=30) were enrolled and divided into three groups according to the PPI they received: lansoprazole (LPZ)-combined, rabeprazole (RPZ)-combined, and non-PPI-combined groups. We compared the blood concentrations of TAC or CSA and the incidences of adverse events among the three groups. CYP2C19 gene polymorphisms were also assessed to investigate its influence on the blood concentration of TAC or CSA. Results LPZ significantly increased the blood concentration of TAC 12 hours after TAC administration (p=0.030 and p=0.003, respectively) and CSA (p=0.047 and p=0.014, respectively) in comparison with RPZ and non-PPI-combined treatment. There were no significant differences in the mean CSA blood concentration two hours after administration in patients with or without PPI treatment, in the incidence of adverse events, or in the CYP2C19 gene polymorphism status among the three groups. Conclusion Combining agents that are mainly metabolized by CYP3A4 such as LPZ elevates the blood concentrations of TAC and CSA, which could leading to adverse events.

30 September 2022 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
EKEiji Kawasaki
Eiji Kawasaki
ASAkira Shimada
Akira Shimada
AIAkihisa Imagawa
Akihisa Imagawa
NANorio Abiru
Norio Abiru
TATakuya Awata
Takuya Awata
HIHiroshi Ikegami
Hiroshi Ikegami
Aims/Introduction: This study aimed to investigate the clinical significance and antigen specificity of autoantibodies to insulinoma‐associated antigen‐2 (IA‐2A) by radioimmunoassay (RIA; IA‐2A‐RIA) and enzyme‐linked immunosorbent assay (ELISA; IA‐2A‐ELISA) in Japanese patients with type 1 diabetes.Materials and Methods: A total of 338 type 1 diabetic patients were enrolled, including 38 fulminant type 1 diabetes, 168 acute‐onset type 1 diabetes and 137 slowly‐progressive type 1 diabetes (SPIDDM). The concordance, correlation of autoantibody titer, and the relationship between IA‐2A and progression to the insulin‐deficient state were examined. Also, competitive assay was used to examine the antigen specificity.Results: The prevalence of IA‐2A‐ELISA was 4–5% lower than that of IA‐2A‐RIA in both the acute‐onset type 1 diabetes and SPIDDM, but the diagnostic sensitivities of both subtypes, when measured in combination with glutamic acid decarboxylase autoantibody, were comparable. The diagnosis of type 1 diabetes using either the RIA or ELISA methods showed substantial agreement with the exponential correlation of autoantibody titers detected by RIA and ELISA. Among the SPIDDM patients, the fasting C‐peptide for IA‐2A‐positive cases by ELISA, but not the RIA method, was significantly lower than in the negative cases (P < 0.05). Furthermore, IA‐2A‐ELISA proved superior to the RIA method in predicting the progression to insulin deficiency in SPIDDM. Competitive analysis showed that even sera with discrepant results by RIA and ELISA have IA‐2‐specific autoantibodies.Conclusion: These results suggest that IA‐2A‐ELISA is a reliable marker not only for the diagnosis of type 1 diabetes, but also for the prediction of future insulin dependency; that is, detection of IA‐2A‐ELISA helps identify a subtype of SPIDDM patients who would likely progress onto insulin‐deficient state.

1 January 2005 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HMHideyuki Muraoka
Hideyuki Muraoka
NNNobuyuki Negoro
Nobuyuki Negoro
FTFumio Terasaki
Fumio Terasaki
TNTakahiro Nakakoji
Takahiro Nakakoji
SKShigeyuki Kojima
Shigeyuki Kojima
THToshiaki Hanafusa
Toshiaki Hanafusa
A 69-year-old man with a recurrent ventricular tachycardia (VT) was admitted. The patient was diagnosed as myotonic dystrophy type 1 (DM1) and DNA analysis revealed 1,800 CTG-repeat expansion in the myotonic dystrophy protein kinase (DMPK) gene. Ultrasonic cardiogram (UCG), left ventriculogram (LVG) and magnetic resonance imaging (MRI) did not show any abnormal sign including fatty infiltration. But, endomyocardial biopsy obtained from ventricular outflow tract revealed severe fatty infiltration and interstitial fibrosis. Radiofrequency catheter ablation at the biopsy site could eliminate VT, so it was strongly suggested that the re-entry circuit was formed by focal fatty-fibrosis. Careful observation should be continued for a long period.